Fig. 2From: Weight gain and comorbidities associated with oral second-generation antipsychotics: analysis of real-world data for patients with schizophrenia or bipolar I disorderProportion of Patients With CSWG During Treatment With Oral SGAs of Moderate to High Weight Gain Risk. BD-I, bipolar I disorder; CSWG, clinically significant weight gain; SGA, second-generation antipsychotic; SZ, schizophrenia; Tx, treatmentBack to article page